Tacrolimus Impurity 1 is chemically [3S-[3R*[E(1S*,3S*,4S*)],4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,25aR*]]- 3,4,5,6,8,11,12,13,14,15,16,17,18,19,23,24,25,25a-Octadecahydro-5,19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxypyrido[2,1-c][1,4]oxaazacyclodocosine-1,7,20(22H)-trione. Tacrolimus Impurity 1 is supplied with detailed characterization data compliant with regulatory guideline. Tacrolimus Impurity 1 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Tacrolimus.
关键字： 医药对照品;
祥根生物医药于2008年12月成立，是一家集药物研发、生产、销售的创新型医药高科技企业，荣获“国家高新技术企业”和“博士后实践创新基地”等称号。祥根生物医药拥有药物成分标准物质、关键中间体、原料药与药品进出口全产业链平台。祥根是众多全球知名标准品（Aozeal/USP/EP/LGC/Bachem/TLC/TRC/意大利试剂等）和原料药（INKE/Bachem/瑞迪/意迪那等）总代理和授权代理商，处于行业领先水平。
祥根生物医药拥有一个尊重人才、重视绩效、持续创新的平台。 研发团队由多名海外高层次人才领衔，研发人员50余人；获得相关发明专利30余项。祥根生物医药的企业责任是：回报员工、回报合作伙伴、回报社会；企业愿景是：提升药品质量，保护人类健康。